Key result
Doxorubicin plus cisplatin yielded a 26% overall response rate compared to 17% with doxorubicin alone (P>0.1), but produced significantly more complete responses (5 vs 0, P=0.03).
Why the study?
Does doxorubicin plus cisplatin improve response rates compared to doxorubicin alone in patients with advanced thyroid carcinoma?
Population
92 patients (84 evaluable) with advanced thyroid carcinoma
Comparison
Doxorubicin plus cisplatin combination therapy vs Doxorubicin alone
Design
RCT, Stratified according to histological classification, ECOG performance…
Follow-up
> 2 years
Authors
Loading...
Does not improve overall response rates in advanced thyroid carcinoma; leaves open whether complete response gains merit further trials.
RCT (n=92)
Stratified
Does doxorubicin plus cisplatin improve response rates compared to doxorubicin alone in patients with advanced thyroid carcinoma?
Absolute Event Rate: 26% vs 17%
p-value: p=>0.1
The combination of doxorubicin and cisplatin yields a significantly higher complete response rate than doxorubicin alone in advanced thyroid carcinoma, though overall response rates are similar.
Shimaoka et al. (1985) conducted an RCT in Advanced thyroid carcinoma (n=92). Doxorubicin plus cisplatin vs. Doxorubicin alone was evaluated on Overall response rate (p=>0.1). Doxorubicin plus cisplatin yielded a 26% overall response rate compared to 17% with doxorubicin alone (P>0.1), but produced significantly more complete responses (5 vs 0, P=0.03).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: